 |
Withdrawal of Permax* (pergolide)On March 29, 2007, the FDA issued a Public Health Advisory announcing that manufacturers of pergolide drug products would voluntarily remove these drugs from the market because of the increased chance of regurgitation of the mitral, tricuspid, and aortic valves of the heart associated with the use of this drug. The products being withdrawn are Permax, the trade name for pergolide marketed by Valeant Pharmaceuticals and two generic versions of pergolide manufactured by Par and Teva. As of March 29, 2007, Permax (pergolide) is no longer available on the market, has been removed from the CIGNA formulary, and no coverage will be available for it. Letters were sent to CIGNATURE-Rx members currently receiving Permax, informing them of the withdrawal, and advising that they contact their physician as soon as possible to determine what other alternatives are availabe to treat their conditions. Furthermore, letters were sent to physicians identifying patients for whom they recently prescribed Permax. Additional information regarding the Permax (pergolide) withdrawal is available via:
|
| CIGNA | CIGNA Sites |
|